|Awarded On||May 21, 2014|
|Title||Preclinical and Clinical Development of Synergistic MicroRNA + Targeted Drug Combinations|
|Program||Product Development Research|
|Award Mechanism||Established Company|
|Institution/Organization||Mirna Therapeutics, Inc.|
|Principal Investigator/Program Director||Vincent O'Neill|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct, Lung and Bronchus|
Mirna Therapeutics, Inc., is a Texas-based company developing a new class of cancer treatments that are based on naturally occurring tumor suppressor microRNAs. In April 2013, Mirna’s lead product, a liposomal mimic of miR-34 (MRX34), entered a Phase I clinical trial for liver cancer. Key benefit of these therapies is the ability to simultaneously block multiple cancer processes which is important for the successful treatment of cancer that frequently originates from multiple mutations and thrives on multiple pathways. The ability to interfere with multiple cancer pathways is a new paradigm in cancer therapy that has the potential to create more effective cancer drugs.
Because most cancer dr...